Medincell Reports FY 2025-26 Annual Results
Medincell Reports FY 2025-26 Annual Results
A year marked by solid execution, with
Continued UZEDY® ramp-up, supporting royalty growth
Olanzapine LAI advancing into regulatory review ahead of its expected U.S. launch in Q4 2026 by Teva1
The first AbbVie program progressing toward the initiation of clinical development
Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere,…
After doubling sales of its Biogen-partnered Alzheimer’s disease med Leqembi in its 2025 fiscal year, Eisai figures the crawl to…
As its ultra-rare disease med Miplyffa strengthens its foothold in the U.S., Zevra Therapeutics’ CEO believes the launch has the…
Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S.…
BioArctic Interim Report for the period January - March 2026
